Evonik Industries AG (ETR:EVK)
19.61
-0.08 (-0.41%)
May 13, 2025, 11:38 AM CET
Evonik Industries AG Revenue
Evonik Industries AG had revenue of 3.78B EUR in the quarter ending March 31, 2025, a decrease of -0.50%. This brings the company's revenue in the last twelve months to 15.14B, up 0.53% year-over-year. In the year 2024, Evonik Industries AG had annual revenue of 15.16B, down -0.72%.
Revenue (ttm)
15.14B
Revenue Growth
+0.53%
P/S Ratio
0.61
Revenue / Employee
493.59K
Employees
30,669
Market Cap
9.18B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 15.16B | -110.00M | -0.72% |
Dec 31, 2023 | 15.27B | -3.22B | -17.42% |
Dec 31, 2022 | 18.49B | 3.53B | 23.62% |
Dec 31, 2021 | 14.96B | 2.76B | 22.59% |
Dec 31, 2020 | 12.20B | -909.00M | -6.93% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BASF SE | 65.11B |
Heidelberg Materials AG | 21.25B |
Symrise AG | 5.00B |
Covestro AG | 14.15B |
Brenntag SE | 16.24B |
Wacker Chemie AG | 5.71B |
K+S Aktiengesellschaft | 3.65B |
LANXESS Aktiengesellschaft | 6.36B |
Evonik Industries AG News
- 17 hours ago - Evonik Industries AG (EVKIF) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 21 hours ago - Evonik Industries reports Q1 results - Seeking Alpha
- 5 weeks ago - Evonik: Decent Rate Of Return, Upside Confirmed - Seeking Alpha
- 2 months ago - Evonik Industries AG (EVKIF) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Evonik Industries reports Q4 results; initiates Q1 and FY25 outlook - Seeking Alpha
- 5 months ago - Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development - Benzinga
- 5 months ago - EQS-News: Feasibility Study with Evonik Confirms LEON’s FR-JET Technology’s Performance in Advanced Nanoparticle Manufacturing for Drug Delivery - Wallstreet:Online
- 5 months ago - Evonik: A Good Company, Upside Less Clear Than Before - Seeking Alpha